BioStack, a healthcare technology startup founded by Sanat Mishra, has raised $9.5 million in a seed funding round to expand an international health‑data infrastructure that includes India among its target markets. The round was led by Peak XV, Afore Capital and DCVC, with participation from Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator.
What the funding will be used for
The company said the fresh capital will support its international expansion, further development of its technology platform, and growth of its engineering and research teams. BioStack is building a network of de‑identified clinical records that it says already spans the United States, India, Brazil and Argentina.
- Scale of data: access to more than 100 million de‑identified patient records, according to the company.
- Types of records: longitudinal patient records combining clinical notes, lab results, medical imaging, medications, treatment histories and outcomes.
- Clinical assets: several hundred thousand X‑rays, MRI and CT scans, and millions of telehealth audio transcripts and other clinical records.
How BioStack works and who it serves
BioStack’s platform aims to connect fragmented clinical information held in separate hospital systems into unified, longitudinal records. From those de‑identified records the company builds proprietary datasets intended for medical research, drug development and the training and evaluation of healthcare AI models. The startup lists applications such as disease modelling, biomarker discovery, patient stratification and analysis of treatment response.
In India, the company is also working to link cancer patients with an investigational cancer vaccine programme, and its platform includes workflows adapted to the data privacy protocols of individual healthcare providers.
Investors and structure
The seed round was led by Peak XV, Afore Capital and DCVC. Other participants named by the company include Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator. The company did not disclose a valuation in the statements provided.
| item | detail |
|---|---|
| Funding | $9.5 million (seed) |
| Lead investors | Peak XV, Afore Capital, DCVC |
| Other backers | Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, Y Combinator |
| Data footprint | Access to more than 100 million de‑identified patient records |
BioStack was founded to address the problem of clinical data fragmentation — where notes, test results and imaging are stored in different systems — and to produce datasets that can be used in regulated medical research and to train AI models. The company says its platform is designed to respect provider privacy protocols while enabling research and product development that rely on multi‑modal clinical data.
For Indian hospitals, research centres and regulators, startups such as BioStack represent both an opportunity and a set of questions about de‑identification, data governance and access for AI training. The company’s reported work connecting patients to a cancer vaccine programme in India signals direct engagement with local clinical pathways alongside its broader international ambitions.
